Kulkanya Chokephaibulkit, MD

Biography

Dr. Kulkanya Chokephaibulkit has served as a Faculty member in the Department of Pediatrics at the Faculty of Medicine Siriraj Hospital since June 1995. She was the Head of the Pediatric Infectious Diseases Unit from 2008 to 2020 and currently serves as a Consultant for the unit as well as the Siriraj Institute of Clinical Research (SICRES). A distinguished leader in her field, she is the President of the Pediatric Infectious Disease Society of Thailand (2022-present) and serves as a Member of the National Vaccine Committee for the Ministry of Public Health, Thailand.

Education & Credentials

• M.D. (Honor) – Faculty of Medicine, Siriraj Hospital, Bangkok Thailand (1985)
• Diplomate, Thai Board of Pediatrics – Faculty of Medicine, Siriraj Hospital, Bangkok Thailand (1988-1991)
• Diplomate, American Subboard of Pediatric Infectious Diseases – Cedars-Sinai Medical Center, California, USA (1992-1994)
• Diplomate, American Board of Pediatrics – University of Tennessee at Knoxville, Tennessee, USA (1994-1995)
• Epidemiology (EIS) – The Rollins School of Public Health at Emory University and The Center for Disease Control and Prevention USA (1994)

Research Interests

• Adverse Events Following Immunization (AEFI) and National Vaccine Initiatives
• Pediatric HIV/AIDS management, prevention, and clinical trials (IMPAACT Principal Investigator)
• COVID-19 vaccination immunogenicity, reactogenicity, and variant efficacy
• Dengue vaccine development and tropical infectious diseases

Selected Publications

• Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations. Front Immunol, 2023.
• Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis. Asian Pac J Allergy Immunol, 2022.
• Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV, 2022.
• A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age. Vaccine, 2022.